Lee JM, Moore RG, Ghamande S, Park MS, et al. Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial. Clin Cancer Res 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
PMID: 35917514